List of Studies ( Metabolite:5,6-EpETrE)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Analysis Type |
|---|---|---|---|---|---|---|---|
| ST003222 | AN005283 | A small molecule macrophage migration inhibitory factor agonist ameliorates age-related myocardial intolerance to ischemia-reperfusion insults via metabolic regulation - Part 1 | Heart | Mouse | Ischemia | University of Mississippi Medical Center | LC-MS |
| ST003063 | AN005018 | Uncoupling Metabolic Health from Thermogenesis via BCAA Nitrogen Flux in Brown Fat - Serum metabolomics from control and MBC UCP1-KO | Blood | Mouse | Diabetes | BIDMC | LC-MS |
| ST003050 | AN005001 | Plasma instead of serum avoids critical confounding of clinical metabolomics studies by platelets (Part 1) | Blood | Human | University of Vienna | LC-MS | |
| ST002977 | AN004888 | Offline Two-dimensional Liquid Chromatography-Mass Spectrometry for Deep Annotation of the Fecal Metabolome following Fecal Microbiota Transplant | Feces | Human | University of Michigan | LC-MS | |
| ST002455 | AN004005 | Organism-Wide Analysis of Sepsis Reveals Mechanisms of Systemic Inflammation | Blood | Mouse | Sepsis | University of Chicago | LC-MS |
| ST002354 | AN003843 | Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. | Blood | Rat | Cancer | UConn Health | LC-MS |
| ST002354 | AN003843 | Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. | Colon | Rat | Cancer | UConn Health | LC-MS |
| ST002354 | AN003845 | Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. | Blood | Rat | Cancer | UConn Health | LC-MS |
| ST002354 | AN003845 | Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. | Colon | Rat | Cancer | UConn Health | LC-MS |
| ST001951 | AN003176 | Quantification of ω-3 fatty acids and their derivatives in lungs from hypoxia-induced pulmonary hypertension (PH) mice. | Lung | Mouse | Pulmonary hypertension | University of Tokyo | LC-MS |
| ST001215 | AN002026 | Effect of Mirabegron Treatment on serum lipidome | Blood | Human | Joslin Diabetes Center | LC-MS | |
| ST001214 | AN002025 | Lipidommics in the serum of human subjects | Blood | Human | Joslin Diabetes Center | LC-MS | |
| ST001213 | AN002024 | Serum lipidomic profile of cold-exposed Ucp1cre/12-LOX KO mice | Blood | Mouse | Joslin Diabetes Center | LC-MS | |
| ST001207 | AN002009 | Lipidomics in the serum of cold exposed mice treated with 12-LOX inhibitor LOXBlock-1 | Blood | Mouse | Joslin Diabetes Center | LC-MS | |
| ST001206 | AN002008 | Effects of cold exposure on serum lipidomic in mice | Blood | Mouse | Joslin Diabetes Center | LC-MS | |
| ST000915 | AN001485 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Liver | Liver | Human | Fatty liver disease | LIPID MAPS | GC-MS/LC-MS |
| ST000004 | AN000004 | Lipidomics studies on NIDDK / NIST human plasma samples | Blood | Human | LIPID MAPS | LC-MS |
